Last reviewed · How we verify
Pyronaridine-artesunate tablets
At a glance
| Generic name | Pyronaridine-artesunate tablets |
|---|---|
| Also known as | Pyramax tablets, PA tablets |
| Sponsor | Medicines for Malaria Venture |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers (PHASE1)
- Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate (PHASE1)
- The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3) (PHASE3)
- Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet (PHASE1)
- Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyronaridine-artesunate tablets CI brief — competitive landscape report
- Pyronaridine-artesunate tablets updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI